For BRCA2‐associated cancers where validated cancer‐specific PGS are available (breast, prostate, pancreas, ovary, larynx, lung, and oral), each PGS was associated with the respective cancer risk, independent of BRCA2 PV carrier status, p < 0.001 (Table 2). This evidence concerns the gene BRCA2 and cancer.